- Headquarters: California
- Founded: 2008
- oncosec.com
OncoSec Medical to Present Updated Clinical and Immune Biomarker Data from its Monotherapy and Combination Therapy Studies with ImmunoPulse IL-12 at the 9th World Congress of Melanoma - A Joint Meeting with the Society for Melanoma Research
Co will present new clinical data on ImmunoPulse IL-12 (intratumoral pIL-12 "tavo" with electroporation), its lead program focused on oncology, at the upcoming 9th World Congress of Melanoma -- A Joint Meeting with the Society for Melanoma Research (SMR). In addition, Chris Twitty, Ph.D., Executive Director of Clinical Science, gave an oral presentation at the 2nd Annual Biomarkers & Precision Medicine USA Congress earlier this week.
"These data, along with the emerging clinical data from the phase 2 combination study, further support the rationale for our global, open-label, registration directed phase 2b clinical trial, PISCES/KEYNOTE-695, which we anticipate reporting initial data in mid-2018."
No comments:
Post a Comment